HGEN - Humanigen and Avid Bio ink manufacturing deal for lenzilumab in COVID-19

Avid Bioservices (CDMO), up 7% premarket and Humanigen (HGEN) have entered into a manufacturing services agreement to expand production capacity for lenzilumab, latter's therapeutic candidate in development for COVID-19.Under the terms of this cGMP agreement, Avid will initiate technical transfer and analytical validation activities for lenzilumab with the goal of delivering cGMP drug substance batches to support Humanigen’s regulatory and potential commercial activities.This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization and subsequent BLA later this year.

For further details see:

Humanigen and Avid Bio ink manufacturing deal for lenzilumab in COVID-19